Corrigendum to "Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]

The authors regret that an error occurred in their supplementary material. In the published article, “Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC” (Garassino MC et al, JTO Clin Res Rep. 2022 Nov 8;4:100431), a typographical error has come to our attention. In Supplemental Figure 9, two bars were incorrectly labeled as “Placebo + Chemo” and "Pembro + Chemo” when they should have been labeled as “Pembro + Chemo and “Placebo + Chemo”. Labeling of these bars has been corrected in the current Supplemental Material. The authors apologise for any inconvenience caused.